Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163945 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL698428 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL6163541 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL8332466 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL8896528 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL2254535 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL2255805 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL5508667 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL2892144 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 | |
| SCHEMBL5517470 | 0.98 | DGKA (0.57) | DGKATSHRLMNAPAMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0643059-A1 | 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors | Pfizer Limited (GB) | 1995-03-15 | — | — | EP | claimed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |
| US-4613614-A | Prostaglandin I2 ester and fat emulsion containing the same | THE GREEN CROSS CORPORATION (JP) | 1986-09-23 | — | — | US | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| CN-113316564-B | Fused tricyclic deuterated derivative, and composition and application thereof | 四川海思科制药有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023063154-A1 | TRACER COMPOSITION FOR RADIOACTIVE PET DIAGNOSIS, INTERMEDIATE THEREOF, AND PRODUCTION METHOD THEREOF | 国立大学法人大阪大学 | 2023-04-20 | — | — | WO | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| EP-0227640-A1 | Polyolefins stabilised by bis-(polyalkylpiperidinyl-amino)-1,3,5-triazines | CIBA-GEIGY AG (CH) | 1987-07-01 | — | — | EP | disclosed |
| US-4613614-A | Prostaglandin I2 ester and fat emulsion containing the same | THE GREEN CROSS CORPORATION (JP) | 1986-09-23 | — | — | US | disclosed |
| US-4605651-A | BACTERICIDES | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0108942-A2 | Cephalosporin derivatives, methods of production thereof and prophylactic and therapeutic agents for bacterial infection | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1984-05-23 | — | — | EP | disclosed |
| EP-0107615-A1 | Polyolefins stabilized by bis or tris (polyalkylpiperidinyl-amino) 1,3,5-triazines | CIBA-GEIGY AG (CH) | 1984-05-02 | — | — | EP | disclosed |
| US-4229345-A | (2-Chloro-4-cyanophenyl) (4-dialkylaminophenyl)-diazine dye useful for transfer printing | BASF AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-3994939-A | BACTERICIDES | PFIZER INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | DGKA 2103/4885TSHR 1530/4885LMNA 1254/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | DGKA 2469/4885TSHR 1572/4885LMNA 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.